Despite A Third Failure, Merck KGaA And GSK Won’t Give Up On Bintrafusp Yet

More Read-Outs To Come

 
• By Andrew McConaghie

After three failures in quick succession, Merck needs to see a win in one of its many remaining Phase II trials.

Merck KGaA Darmstadt
Merck KGaA and GSK's multi-target deal was worth up to $4.2bn, but three failures have seen its likely value decline.

More from Clinical Trials

More from R&D